Although further research is needed to identify the mechanisms by which SGLT-2 inhibitors affect fatty liver and steatohepatitis, several trials in patients with type 2 diabetes have suggested that these drugs may be useful in treating both type 2 diabetes and NAFLD or NASH (41–46). This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatohepatitis.